Which combination inhaler contains a corticosteroid and a long-acting beta agonist?

The combination inhaler that contains both a corticosteroid and a long-acting beta agonist is Seretide. This inhaler is specifically designed to provide dual action for managing asthma and chronic obstructive pulmonary disease (COPD). The corticosteroid component works to reduce inflammation in the airways, which helps prevent asthma attacks and manages ongoing symptoms, while the long-acting beta agonist component facilitates bronchodilation by relaxing the muscles around the airways, making it easier for patients to breathe.

In contrast, Pulmicort primarily consists of a corticosteroid and does not contain a long-acting beta agonist, making it suitable for anti-inflammatory purposes but lacking the bronchodilation effect provided by the beta agonist. Rexair is not a recognized medication for asthma or COPD treatment, and Flixotide, like Pulmicort, is solely a corticosteroid without a long-acting beta agonist component. Thus, Seretide is the correct choice as it effectively combines these two classes of medication for enhanced therapeutic efficacy.